Hoba, a Danish biotech from Novo, raises $25M to crack into difficult pain and hearing loss fields

No­vo Hold­ings-found­ed biotech Ho­ba Ther­a­peu­tics has raised $25 mil­lion in the first close of a Se­ries A fi­nanc­ing to bankroll its in­ves­ti­ga­tion­al med­i­cines for pain and hear­ing loss.

Copen­hagen-based Ho­ba, which got its start about sev­en years ago af­ter ac­quir­ing IP from Neu­roSearch spin­off Ns­Gene, has a non-opi­oid can­di­date that it hopes could fol­low in the foot­steps of Ver­tex Phar­ma­ceu­ti­cals’ lead­ing pro­gram. Boston-based Ver­tex is on the verge of a late-stage read­out for its can­di­date VX-548 for acute pain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.